Uniphore Acquiring ActionIQ and Infoworks to Deliver the Industry’s First Zero Data AI Cloud
5.12.2024 11:57:00 CET | Business Wire | Press release
Strategic acquisitions unleash Enterprise data to create knowledge, fine tune AI models, create powerful AI agents and drive business transformation.
Uniphore, the global leader in Enterprise AI, today announced it is acquiring two industry-leading data powerhouses, ActionIQ and Infoworks, which significantly expands its AI-powered offerings. These strategic acquisitions extend Uniphore’s comprehensive end-to-end Enterprise AI platform and will deliver the industry’s first Zero Data AI Cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205133623/en/

Uniphore is acquiring two industry-leading data powerhouses, ActionIQ and Infoworks, which significantly expands its AI-powered offerings. These strategic acquisitions extend Uniphore’s comprehensive end-to-end Enterprise AI platform and will deliver the industry’s first Zero Data AI Cloud. (Graphic: Business Wire)
A Zero Data AI Cloud enables enterprises to overcome the largest barriers of AI adoption – data access, accuracy, flexibility and data sovereignty. It removes data bottlenecks and delivers powerful AI capabilities while preserving customers’ existing data landscape and avoids complex integration challenges. Uniphore’s Zero Data AI Cloud is built on an infrastructure-agnostic architecture that creates a seamless data fabric across any data platform, enterprise application, or cloud environment.
By bringing Uniphore, ActionIQ and Infoworks together, enterprise customers will have access to an entire suite of AI capabilities that empowers organizations to move beyond proof-of-concept AI trials into full scale implementation, accelerating their digital transformation.
In addition to their industry-leading customer data solutions, ActionIQ brings their Composable Zero-copy Data Platform, which enables enterprises to connect all data, from anywhere, and make it AI-ready without requiring any long integration or ETL projects. Infoworks brings their Enterprise Data Platform which includes intelligent AI data agents that can discover, identify, organize, catalogue and clean enterprise data with little human supervision.
Their combined expertise and innovative technology enable enterprises to leverage all their data for AI initiatives without the need to move, transform, or copy it, and will accelerate the time to achieve results down to weeks, not years, all while maintaining high standards of governance and security.
“This is a defining moment for Enterprise AI,” said Umesh Sachdev, CEO and co-founder of Uniphore. “With the acquisitions of ActionIQ and Infoworks, Uniphore is enabling a Zero Data AI Cloud for the world’s largest companies, equipping them with the tools to fast-track AI deployments and drive measurable business outcomes.”
Tasso Argyros, CEO and co-founder of ActionIQ said, "At ActionIQ we’ve been hyper-focused on data and helped create and now lead the massive category of Customer Data Platforms, helping dozens of F1000 enterprises transform their Customer Experience. It is my belief that the future of CDPs is AI and CX Agents. Bringing together Uniphore's industry-leading AI capabilities and ActionIQ's data and CX capabilities will allow us to continue leading the market and deliver world class solutions to the world.”
"Data has long been a challenge for enterprises to modernize their operations and embracing AI innovations," said Amar Arsikere, Founder at Infoworks. "At Infoworks, we are redefining data engineering with groundbreaking automation that seamlessly handles every data task for any kind of data. By joining forces with Uniphore, we now deliver a comprehensive Data + AI solution that accelerates the development of Enterprise AI applications and empowers organizations to unlock their full potential."
Powering Business Transformation with a Zero Data AI Cloud
Uniphore is pioneering a revolutionary approach leveraging a multi-layered AI architecture comprised of a composable data layer, knowledge layer, model layer and agentic layer. Within each layer, Uniphore has feature-rich solutions, with continued investments planned in each area.
- Composable Data Layer
Organizations can instantly harness their enterprise data without complex migrations or copies. Enterprises can maintain complete control of their data assets across global operations. It reduces AI deployment time from months to weeks.
- Knowledge Layer
Enterprise data is transformed into an AI-ready knowledge lake. It ensures that AI outputs are grounded in an organization’s business reality without hallucinations. This allows organizations to fully leverage and protect their institutional knowledge and experience.
- Model Layer
All the capabilities in this layer enable countless options for enterprises to easily pick relevant foundational models and/or work with multiple models to meet their business needs. Within the model layer there are also tooling capabilities to easily create fine-tuned industry and enterprise specific small language models.
- Agentic Layer
This is where digital transformation is accelerated with ready-to-deploy AI agents across core functions such as customer service, marketing, HR, sales, and more. Further, this layer empowers the functional user and citizen developer to build and manage intelligent and personalized AI agents for specific business needs and workflow automation.
With this unique 4-layer approach, customers now can fully leverage Uniphore’s suite of end-to-end AI capabilities through an open architecture, while ensuring data sovereignty and enterprise-grade scalability. Organizations maintain complete control while deploying AI solutions across any scale—from department level solutions all the way to sophisticated global operations.
Enterprise AI That Delivers Results
Large enterprises are increasingly looking for solutions that enable them to become more agile, responsive, and data-driven in their decision-making. With the acquisition of ActionIQ and Infoworks, Uniphore is the only Enterprise AI company with an end-to-end solution for a Zero Data AI Cloud that delivers:
- Accelerated Time to Value
Now, customers can deploy enterprise-wide AI solutions in weeks, by enabling seamless data access. With support for multi-cloud and virtual private cloud deployments, enterprises’ needs for flexible and secure access to data are achieved. Further, Uniphore delivers enterprises an end-to-end AI stack with pre-built applications today for customer service, sales, HR, marketing, and more as well as the capabilities to build their own intelligent agents.
- Superior AI Performance
High accuracy is now attainable because of fine-tuned industry and enterprise models that access an enterprise’s knowledge in any data format. The Uniphore solution also delivers consistent results aligned with any company’s business context beyond what traditional RAG solutions provide. Because of Uniphore’s open architecture and orchestration capabilities, enterprises can leverage their existing best-in-class solutions, based on business needs, to support multiple models.
- Enterprise Data Freedom
The Uniphore Zero Data AI Cloud enables the use of multi-modal data across any platform, architecture, or application. There no longer needs to be any disruption to existing systems and workflows and no vendor lock-in. This gives customers complete control over sensitive enterprise knowledge and information.
This strategic move from Uniphore cements its leadership position as an Enterprise AI innovator. Uniphore will continue to deliver industry-leading solutions, including expanding the ActionIQ composable CDP solution to capitalize on the multi-billion-dollar CDP market opportunity and will continue to enhance its established portfolio of solutions that currently are in use at some of the world’s largest corporations. The ActionIQ solution is currently listed as a leader in the Forrester Wave competitive report on Customer Data Platforms.
For additional information on these acquisitions, please see our information page, which has a fact sheet on ActionIQ and afact sheet on Infoworks. Tidal Partners LLC acted as exclusive financial advisor to Uniphore on the transaction.
About Uniphore
Uniphore is a leading B2B AI-native company with decades of proven success. Engineered for scalability and tailored for enterprise needs, we drive AI transformation that delivers real business impact across multiple industries and the largest global deployments. Our Zero Data AI Cloud is built on a multimodal AI and data platform and is at the heart of this transformation, enabling businesses to swiftly deploy AI across the enterprise. With our Zero-Data AI Cloud, organizations can harness their data and create scalable, domain-specific AI models to democratize enterprise knowledge—all while ensuring security, sovereignty, and rapid value delivery. Today, Uniphore’s technology empowers over 750,000 end-users across 1,600 enterprises in 20 countries. Discover the unmatched capabilities of Uniphore—because there’s no AI like it™.
For more information about Uniphore’s solutions, visit [www.uniphore.com]
View source version on businesswire.com: https://www.businesswire.com/news/home/20241205133623/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom